欧博ABG

2023年7月14日，由Drugverse协办的CIC2023中国化学药物产业链发展峰会（CHINA CHEMICAL DRUG INDUSTRIAL DEVELOPMENT CONFERENCE）取得圆满成功！ The CIC2013 China Chemical Drug Industrial Development Summit, co-organized by Drugverse, was successfully held on July 14, 2023. The summit brought together experts, scholars, and industry leaders from the related fields to discuss the latest trends, challenges and opportunities in chemical drug development. The summit also showcased the innovative solutions and products offered by Drugverse, a platform that aims to help pharmaceutical researchers in their drug development process. The summit was a great opportunity for networking, learning, and collaboration among the participants.

中国科学院院士、中国科学院上海有机化学研究所研究员马大为参加峰会并为大会开幕致辞，发表关于“小分子创新药物发展的思考”的主旨演讲.

Ma Dawei, an academician of Chinese Academy of Sciences and a researcher at the Shanghai Institute of Organic Chemistry of the Chinese Academy of Sciences, attended the summit and gave an opening speech. He also delivered a keynote speech on “Thoughts on the Development of Innovative Small Molecule Drugs”, in which he shared his insights and perspectives on the current status and future trends of small molecule drug research.

健艾仕（杭州）生物制药公司董事长傅新元，进行“化学药靶点选择：以JAK- STAT 为例”的精彩分享。 Fu Xinyuan, the Chairman of the Board of GenEros (Hangzhou) Biopharma Ltd., delivered an insightful presentation on “Chemical Drug Target Selection: Using JAK-STAT as a Case Study”.

峰会就“新时代小分子创新药”设置圆桌讨论环节。如何评价一项创新药研发项目的商业潜力和投资价值？小分子创新药的研发是否能满足未来医学需求？如何加强中国创新药研发人才培养和引进，提高我国在全球创新药领域的竞争力？小分子创新研发和新技术的融合如何推动医疗创新？围绕这些问题，郎盛投资集团合伙人李佳、维亚生物首席创新官戴晗、烨辉医药科技（上海）有限公司CEO华烨、上海宇道生物技术有限公司联合创始人郁征天，分别作为主持嘉宾，与相关企业代表进行互动交流。

The summit featured a roundtable discussion session on “Innovative Small Molecule Drugs in the New Era”. The session addressed the following questions: How can one assess the commercial potential and investment value of an innovative drug discovery project? How can the R&D of innovative small molecule drugs meet the future medical needs? How can China enhance its talent training and recruitment in the field of innovative drug R&D and improve its global competitiveness? How can the integration of small molecule innovation R&D and new technologies foster medical technology innovation? These discussion sections were hosted by Li Jia, a partner of Lang Sheng Investment Group Co., Ltd.、 Dai Han, the chief innovation officer of Viva Biotech、Hua Ye, the CEO of BioNova Pharmaceuticals (Shanghai) Ltd., and Yu Zhengtian, the co-founder of Shanghai Nutshell Biotech Co., Ltd., respectively. The hosts engaged the participants in a lively discussion on these topics and shared their insights and experiences.

目前，Drugverse的商标持有者为大也医药信息咨询(杭州)有限公司

Drugverse is a trademark owned by Daye Pharmaceutical Information Consulting (Hangzhou) Co., Ltd.

Drugverse创始团队及专家顾问团成员具备15-35年国企、民企资深产业领域经验以及广泛的国内外人才、基金、项目、资源储备。公司目前主要从事医药行业企业信息咨询、战略管理、成果转化、创业辅导陪跑、投融资FA、政府招商引资等服务。

The founders and expert advisors of Drugverse have extensive industrial experience ranging from 15 to 35 years in both state-owned and private enterprises. They also have a rich network of domestic and foreign talents, funds, projects and resources. The company provides various services for the pharmaceutical industry, such as enterprise consulting、strategic management、 research commercialization、 entrepreneurial counseling、investment and financing FA、government investment promotion, etc.